In addition, use of the compound was statistically superior in producing pain-free rates as early as 30 minutes, and significantly more patients reached pain-free status at two hours; this result was sustained for 24 hours without the use of additional medicine.
Trexima, a single tablet combination therapy which contains sumatriptan 85mg, as the succinate salt, formulated with RT Technology, and naproxen sodium 500mg, is currently under review with the FDA.
“These data suggest that a single treatment designed to target multiple mechanisms of migraine may be an effective option for many patients,” said Dr Stephen Silberstein, director of the Jefferson Headache Center and lead study investigator. “In particular, we're excited because these studies show promise at treating associated symptoms of migraine such as neck pain and discomfort and sinus pain and pressure, which can be difficult to alleviate.”
Recent data indicate that the pathophysiology of migraine is complex and that migraine is not merely a vascular problem, but a result of a chain of events that are both vascular and neurological. These events develop early in the migraine process, often long before a patient actually feels the sensation of headache pain.
Migraine pain is believed to be induced not only by the widening of blood vessels, or vasodilation, but also by inflammation, leading to nociception (perception of pain) and central and peripheral sensitization.